AI Stock Analysis - C4 Therapeutics (CCCC)
Analysis generated February 13, 2026.
C4 Therapeutics is focused on developing novel therapies to address various medical needs. The company leverages its proprietary technology targeting protein degradation, aiming to provide new solutions for conditions that currently lack effective treatments. With a commitment to innovation, C4 Therapeutics is positioned at the cutting edge of biotechnology.
Stock Alerts - C4 Therapeutics (CCCC)
 |
C4 Therapeutics | February 10 Price is up by 6.2% in the last 24h. |
|
C4 Therapeutics | February 6 Price is up by 6.4% in the last 24h. |
|
C4 Therapeutics | February 5 Price is down by -6.4% in the last 24h. |
|
C4 Therapeutics | February 4 Price is down by -6.2% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for C4 Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 50 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 86 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,443 | Sign up | Sign up | Sign up |
| X Followers | 1,847 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 63 | Sign up | Sign up | Sign up |
| Linkedin Employees | 110 | Sign up | Sign up | Sign up |
About C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.
| Price | $1.89 |
| Target Price | Sign up |
| Volume | 74,030 |
| Market Cap | $177M |
| Year Range | $1.4 - $3.57 |
| Dividend Yield | 0% |
| Analyst Rating | 71% buy |
| Industry | Biotechnology |
In the news
 |
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 9 - Yahoo |
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026February 4 - GlobeNewswire |
|
C4 Therapeutics, Inc. (CCCC): A Bull Case TheoryFebruary 2 - Yahoo Entertainment |
|
 |
C4 Therapeutics outlines milestones through 2028January 14 - Thefly.com |
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated PathwaysJanuary 14 - GlobeNewswire |
|
 |
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trialFebruary 3 - Nature.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 11M | 0 | 11M | -32M | -32M | -0.295 |
| Q2 '25 | 6.5M | 2.1M | 6.5M | -26M | -28M | -0.370 |
| Q1 '25 | 7.2M | 2M | 7.2M | -26M | -29M | -0.370 |
| Q4 '24 | 5.2M | 1.8M | 3.4M | -35M | -33M | -0.490 |
| Q3 '24 | 15M | 2.1M | 13M | -25M | -23M | -0.350 |
Insider Transactions View All
| REYNO LEONARD filed to sell 156,382 shares at $2.2. January 16 '26 |
| Boyle Scott N filed to sell 107,805 shares at $3.2. February 18 '25 |
| Boyle Scott N filed to sell 110,842 shares at $3.2. February 18 '25 |
| Koppikar Utpal filed to buy 5,667 shares at $5.6. February 10 '23 |
| Hirsch Andrew filed to buy 10,000 shares at $8.4. April 12 '22 |
Similar companies
Read more about C4 Therapeutics (CCCC) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - C4 Therapeutics
The Market Cap of C4 Therapeutics is $177M.
Currently, the price of one share of C4 Therapeutics stock is $1.89.
The CCCC stock price chart above provides a comprehensive visual representation of C4 Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling C4 Therapeutics shares. Our platform offers an up-to-date CCCC stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, C4 Therapeutics (CCCC) does not offer dividends to its shareholders. Investors interested in C4 Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of C4 Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
